Your partner in oncology

oncology therapeUtic development

A boutique CRO focused solely on oncology and onco-hematology.

Specialized in early development of single agent and combination anticancer regimens.



  • Rapid and efficient development of promising new cancer treatments
  • Clinical/preclinical consulting for biotechs and VC groups to guide clinical development
  • Optimize, launch and effectively execute your clinical development plan
  • Interactive support for small and mid-size partners via strong medical input from oncology-experienced staff



  • Execute clinical oncology Phase I/II study design and implementation
  • Real-time data evaluation with continuous oncology input
  • Generate quality data with timely, efficient and cost-effective execution


The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. Vázquez  et al. Oncotarget. 2017;31;8(5):7598-613


OTD - Oncology Therapeutic Development

100 rue Martre
92110 Clichy - FRANCE
Tel:  +33 1 47 15 01 01
Fax: +33 1 45 19 06 59

Contact Us